Bolt Biotherapeutics (BOLT, Financial) experienced a notable stock price increase of 5.32%, with shares trading at $0.679. The trading volume reached 121,025 shares, resulting in a turnover rate of 0.32% and a price fluctuation amplitude of 6.16%.
The company's recent financial report showed revenue of $1.28 million and a net loss of $21.20 million, translating to earnings per share of -$0.56. The gross profit was recorded at $818,000, with a price-to-earnings ratio of -0.39. Out of four rating institutions, 100% recommended holding, with no buy or sell suggestions.
Within the biotechnology sector, Bolt's stock witnessed a decline of 0.11%. Other notable stocks in the sector showed significant activity and fluctuations. Scholar Rock Holding Corporation, Nls Pharmaceutics, and Reviva Pharmaceuticals experienced substantial gains, while Aditxt, Inc., Tc Biopharm Plc, and Phio Pharmaceuticals Corp. demonstrated high turnover rates of 1472.28%, 62.10%, and 55.66%, respectively. Scholar Rock, Reviva Pharmaceuticals, and Revolution Medicines also showed significant price swing amplitudes of 99.06%, 39.46%, and 36.71%.
Bolt Biotherapeutics is a clinical-stage immuno-oncology company developing tumor-targeting therapies by leveraging both innate and adaptive immune systems. Its proprietary Boltbody ISAC platform combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's product pipeline includes BDC-1001, BDC-3042, and Next-Gen ISAC.
